S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Trillium Therapeutics Stock Forecast, Price & News

0.00 (0.00%)
(As of 11/18/2021)
Today's Range
50-Day Range
52-Week Range
8 shs
Average Volume
1.87 million shs
Market Capitalization
$1.94 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive TRIL News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Trillium Therapeutics logo

About Trillium Therapeutics

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.


Trillium Therapeutics (NASDAQ:TRIL) Lowered to Hold at Benchmark
November 17, 2021 |  americanbankingnews.com
Trillium Therapeutics (NASDAQ:TRIL) Sees Strong Trading Volume
November 16, 2021 |  americanbankingnews.com
Is Trillium Therapeutics Inc. (TRIL) A Good Stock To Buy?
October 25, 2021 |  finance.yahoo.com
Why Investors Should Love Pfizer's Acquisition of Trillium
September 4, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$150 thousand
Price / Sales
Book Value
$2.56 per share


Net Income
$-59.35 million
Pretax Margin




Free Float
Market Cap
$1.94 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.71 out of 5 stars

Medical Sector

920th out of 1,390 stocks

Pharmaceutical Preparations Industry

435th out of 668 stocks

Analyst Opinion: 2.1Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Trillium Therapeutics (NASDAQ:TRIL) Frequently Asked Questions

Is Trillium Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Trillium Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRIL, but not buy additional shares or sell existing shares.
View analyst ratings for Trillium Therapeutics
or view top-rated stocks.

How has Trillium Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Trillium Therapeutics' stock was trading at $5.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TRIL shares have increased by 255.3% and is now trading at $18.44.
View which stocks have been most impacted by COVID-19

When is Trillium Therapeutics' next earnings date?

Trillium Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Trillium Therapeutics

How were Trillium Therapeutics' earnings last quarter?

Trillium Therapeutics Inc. (NASDAQ:TRIL) posted its earnings results on Thursday, November, 18th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.01.
View Trillium Therapeutics' earnings history

What price target have analysts set for TRIL?

6 brokers have issued 12 month target prices for Trillium Therapeutics' shares. Their forecasts range from $18.50 to $25.00. On average, they expect Trillium Therapeutics' stock price to reach $20.30 in the next year. This suggests a possible upside of 10.1% from the stock's current price.
View analysts' price targets for Trillium Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Trillium Therapeutics' key executives?

Trillium Therapeutics' management team includes the following people:
  • Jan Skvarka, President, Chief Executive Officer & Director
  • James T. Parsons, Chief Financial Officer
  • Robert A. Uger, Chief Scientific Officer
  • Kathleen Large, Senior Vice President-Clinical Operations
  • Ingmar Bruns, Chief Medical Officer

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Energy Transfer (ET), Gilead Sciences (GILD), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Actinium Pharmaceuticals (ATNM) and Evoke Pharma (EVOK).

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

Who are Trillium Therapeutics' major shareholders?

Trillium Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.82%), Magnetar Financial LLC (3.12%), Omni Partners US LLC (2.25%), Versor Investments LP (1.84%), Gabelli Funds LLC (1.71%) and Westchester Capital Management LLC (1.52%). Company insiders that own Trillium Therapeutics stock include James T Parsons, Jan Skvarka, Penka Petrova and Robert Uger.
View institutional ownership trends for Trillium Therapeutics

Which major investors are selling Trillium Therapeutics stock?

TRIL stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Invesco Ltd., BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Connor Clark & Lunn Investment Management Ltd., Marshall Wace LLP, TD Asset Management Inc., The Manufacturers Life Insurance Company , and California State Teachers Retirement System. Company insiders that have sold Trillium Therapeutics company stock in the last year include James T Parsons, Jan Skvarka, Penka Petrova, and Robert Uger.
View insider buying and selling activity for Trillium Therapeutics
or view top insider-selling stocks.

Which major investors are buying Trillium Therapeutics stock?

TRIL stock was bought by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, Omni Partners US LLC, Versor Investments LP, Westchester Capital Management LLC, Gabelli Funds LLC, CNH Partners LLC, Alpine Associates Management Inc., and Segantii Capital Management Ltd.
View insider buying and selling activity for Trillium Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Trillium Therapeutics?

Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trillium Therapeutics' stock price today?

One share of TRIL stock can currently be purchased for approximately $18.44.

How much money does Trillium Therapeutics make?

Trillium Therapeutics has a market capitalization of $1.94 billion and generates $150 thousand in revenue each year. The biotechnology company earns $-59.35 million in net income (profit) each year or $0.62 on an earnings per share basis.

How many employees does Trillium Therapeutics have?

Trillium Therapeutics employs 33 workers across the globe.

What is Trillium Therapeutics' official website?

The official website for Trillium Therapeutics is www.trilliumtherapeutics.com.

Where are Trillium Therapeutics' headquarters?

Trillium Therapeutics is headquartered at 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at (416) 595-0627 or via email at [email protected].

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.